Products
Platform
Research
Market
Learn
IPO
Compare Mutual Funds
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Fund Details
Risk | Very High | - |
Rating | - | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 2.34 | - |
NAV | ₹13.47 | - |
Fund Started | 20 Nov 2023 | - |
Fund Size | ₹481.04 Cr | - |
Exit Load | 0.5% for redemption within 30 Days | - |
Risk
Very High
-
Rating
-
-
Min SIP Amount
₹100
-
Expense Ratio
2.34
-
NAV
₹13.47
-
Fund Started
20 Nov 2023
-
Fund Size
₹481.04 Cr
-
Exit Load
0.5% for redemption within 30 Days
-
Returns
1 Year | -3.48% | - |
3 Year | - | - |
5 Year | - | - |
1 Year
-3.48%
-
3 Year
-
-
5 Year
-
-
Holding Analysis
Equity | 98.71% | - |
Cash | 1.29% | - |
Equity
98.71%
-
Cash
1.29%
-
Top Holdings
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.36% |
Max Healthcare Institute Ltd. | 7.75% |
JB Chemicals & Pharmaceuticals Ltd. | 5.63% |
Divi's Laboratories Ltd. | 5.60% |
Cipla Ltd. | 4.68% |
Fortis Healthcare Ltd. | 4.25% |
Apollo Hospitals Enterprise Ltd. | 4.23% |
Lupin Ltd. | 3.88% |
Acutaas Chemicals Ltd. | 3.23% |
Jubilant Pharmova Ltd. | 3.20% |
-
Fund Manager
Name | Shibani Sircar Kurian | - |
Start Date | 12 Feb 2024 | - |
Name
Shibani Sircar Kurian
-
Start Date
12 Feb 2024
-
About Fund
Description | The scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors. | - |
Launch Date | 20 Nov 2023 | - |
Description
The scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors.
-
Launch Date
20 Nov 2023
-